M4ND Pharma: Open science drug discovery model expands to neurodegenerative diseases

By | 2019-03-01T20:04:00+00:00 February 16th, 2019|

Medicines for Neurodegeneration (M4ND) Pharma launched! Following in the path of M4K Pharma, M4ND will tackle neurodegenerative diseases such as Parkinson’s disease, thanks to funding from the Krembil Foundation, and will commit to open science practises, open sharing of data, and affordable pricing. https://www.utoronto.ca/news/u-t-researcher-s-open-science-drug-discovery-model-expands-neurodegenerative-diseases  

For Innovation, Open Science Means Open for Business

By | 2019-02-20T12:21:22+00:00 February 7th, 2019|

Richard Gold (McGill University) and Max Morgan (SGC, M4k Pharma) penned an opinion piece in the Globe and Mail discussing how open science projects with no patents can result in local economic development, citing the recent $1Billion investment deal that Celgene signed with the Ontario Institute for Cancer Research (OICR) and their commercialization arm FACIT [...]